I think you have failed to consider the trial design, whereby the dose expansion cohort will recruit adverse risk and elderly patients, but the dose escalation cohort was not subject to this stipulation.
https://www.clinicaltrials.gov/study/NCT05834244?term=NCT05834244&rank=1
They also mention this in the announcement.
On this basis, I'm pretty confident in my assumption that the efficacy reported by CHM has nothing to do with NK Cells and everything to do with Aza-Ven.
Ann: ADVENT-AML Phase 1B clinical trial update, page-82
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 21936206 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24685267 | 27 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |